MedPath

Behavioral Economic Approaches for Population-Based Colorectal Cancer Screening

Not Applicable
Active, not recruiting
Conditions
Colorectal Cancer
Registration Number
NCT05693649
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Brief Summary

This is a 3-year pragmatic, randomized clinical trial among average-risk patients at diverse primary care practices who are overdue for colorectal (CRC) screening. This project aims to evaluate the effect of a centralized program that includes direct outreach to patients and visit-based, clinician directed nudges facilitated by the electronic health record (EHR) with follow-up text messaging on the uptake of CRC screening. The primary outcome is CRC screening completion at 3 years. Patient and clinician factors impacting the experience and effectiveness of the intervention will be explored through surveys and qualitative interviews.

Detailed Description

Despite effective strategies for prevention, early detection, and treatment, colorectal cancer (CRC) remains the second leading cause of cancer death in the United States (US). While there have been considerable policy and system-level efforts to increase CRC screening rates, uptake remains well below national goals of 80% participation. Members of racial and ethnic minorities are even further behind. Approaches to increase population-based screening can consider \[1\] how screening is encouraged by targeting the clinicians who typically order or recommend the procedure or the patient who completes it; and \[2\] the kind of screening offered (e.g., colonoscopy or fecal immunochemical testing \[FIT\]). This project simultaneously tests interventions along both of these dimensions.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
20000
Inclusion Criteria
  • Patients ages 50-72
  • Followed by Primary Care with a participating Penn Medicine PCP listed and at least one visit in the last 2 years
  • Not up to date on colorectal cancer screening per Health Maintenance (no colonoscopy in the last 10 years, stool testing in the last year, flexible sigmoidoscopy in the last 5 years, MT-sDNA in the last 3 years).
Exclusion Criteria
  • Personal or significant family history of CRC, colonic polyps, hereditary nonpolyposis colorectal cancer syndrome, familial adenomatous polyposis syndrome, other gastrointestinal cancer, gastrointestinal bleeding, iron-deficiency anemia, or inflammatory bowel disease
  • History of total colectomy, dementia or metastatic cancer
  • Currently on hospice or receiving palliative care
  • Uninsured or self-pay patients
  • Currently scheduled for a colonoscopy or sigmoidoscopy
  • Active order for multitarget stool DNA testing (MT-sDNA)
  • History of paraplegia or quadriplegia
  • Elevated chance of mortality within 3 years according to mortality risk algorithm
  • Active order for Fecal Immunochemical Test (FIT) in the last 60 days
  • Positive stool test (FIT or MT-sDNA) result in the last 5 years

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Primary Outcome Measures
NameTimeMethod
CRC screening completion at 3 years3 years

CRC screening completion at 3 years, which could be satisfied by any one of the following: colonoscopy completion at any time, negative FIT completed 2 times, or positive FIT followed by diagnostic colonoscopy within 1 year.

Secondary Outcome Measures
NameTimeMethod
Choice of test3 years

The proportion of patients who complete CRC screening by screening type

CRC screening rate3 years

CRC screening completion at 3 years by any modality

Trial Locations

Locations (1)

Penn Medicine

🇺🇸

Philadelphia, Pennsylvania, United States

Penn Medicine
🇺🇸Philadelphia, Pennsylvania, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.